Source link : https://newshealth.biz/health-news/retifanlimab-wins-upfront-indication-for-anal-cancer/
The US Food and Drug Administration has approved two new indications for the PD-1-blocking antibody, retifanlimab-dlwr (Zynyz, Incyte), both for locally recurrent or metastatic squamous cell anal carcinoma. The first indication is for upfront treatment of inoperable disease in combination with carboplatin and paclitaxel; the second is as monotherapy following progression on or intolerance to […]
The post Retifanlimab Wins Upfront Indication for Anal Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-16 14:28:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8